Dr. Reddy’s Laboratories Receives EIR from USFDA for Hyderabad API Facility
Dr. Reddy’s Laboratories has received the USFDA’s Establishment Inspection Report (EIR) for its Hyderabad API facility, signaling regulatory compliance. This comes alongside a strong Q3 FY25 performance, with a rise in net profit and sales, reinforcing the company’s position in the global pharmaceutical market.
